Transparency Life Sciences

Transparency Life Sciences pioneered open innovation in drug development by crowdsourcing input from patients, physicians, and researchers to design more relevant clinical protocols. The company leverages digital health technologies—including telemedicine—to conduct virtual or hybrid clinical trials with reduced costs and improved patient engagement. Its approach has been applied to both new chemical entities and repurposed drugs targeting significant unmet medical needs such as multiple sclerosis, peripheral vascular disease, and inflammatory bowel disease. No published results from late-stage pivotal studies are available in public sources.